Nrg-Gy018- A Phase III Randomized, Placebo-Controlled Study Of Pembrolizumab (Mk-3475, Nsc #776864) In Addition To Paclitaxel And Carboplatin For Measurable Stage III Or Iva, Stage Ivb Or Recurrent Endometrial Cancerchemoradiation Plus Atezolizumab
Posted Date: Mar 6, 2020
- Investigator: Amanda Jackson
- Specialties: Cancer, Oncology
- Type of Study: Drug
The goal of this study is to evaluate the progression free survival of pembrolizumab in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer.
Criteria:
To Be Eligible: Measurable Stage Iii, Iva, Or Ivb, Or Recurrent (With Or Without Measurable Disease) Endometrial Cancer. Ecog 0-2, Normal Tsh Levels, No Hypersensitivities To Study Drugs Or Excipients, No Immunodeficiency, Any Active Or Uncontrolled Illness Or Infection That May Impact Study Results
Keywords:
Endometrial Cancer, Uterine Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com